These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35115506)

  • 41. Bacterial resistance to CRISPR-Cas antimicrobials.
    Uribe RV; Rathmer C; Jahn LJ; Ellabaan MMH; Li SS; Sommer MOA
    Sci Rep; 2021 Aug; 11(1):17267. PubMed ID: 34446818
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulated Expression of sgRNAs Tunes CRISPRi in E. coli.
    Fontana J; Dong C; Ham JY; Zalatan JG; Carothers JM
    Biotechnol J; 2018 Sep; 13(9):e1800069. PubMed ID: 29635744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Strain ŽP - the first bacterial conjugation-based "kill"-"anti-kill" antimicrobial system.
    Starčič Erjavec M; Petkovšek Ž; Kuznetsova MV; Maslennikova IL; Žgur-Bertok D
    Plasmid; 2015 Nov; 82():28-34. PubMed ID: 26436830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems.
    Gomaa AA; Klumpe HE; Luo ML; Selle K; Barrangou R; Beisel CL
    mBio; 2014 Jan; 5(1):e00928-13. PubMed ID: 24473129
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modified viruses deliver death to antibiotic-resistant bacteria.
    Reardon S
    Nature; 2017 Jun; 546(7660):586-587. PubMed ID: 28661508
    [No Abstract]   [Full Text] [Related]  

  • 46. Next-generation biocontainment systems for engineered organisms.
    Lee JW; Chan CTY; Slomovic S; Collins JJ
    Nat Chem Biol; 2018 Jun; 14(6):530-537. PubMed ID: 29769737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A CRISPR-Cas9 System for Genetic Engineering of Filamentous Fungi.
    Nødvig CS; Nielsen JB; Kogle ME; Mortensen UH
    PLoS One; 2015; 10(7):e0133085. PubMed ID: 26177455
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved cryptic plasmids in probiotic Escherichia coli Nissle 1917 for antibiotic-free pathway engineering.
    Dong MM; Song L; Xu JQ; Zhu L; Xiong LB; Wei DZ; Wang FQ
    Appl Microbiol Biotechnol; 2023 Aug; 107(16):5257-5267. PubMed ID: 37405431
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Programmable cells: interfacing natural and engineered gene networks.
    Kobayashi H; Kaern M; Araki M; Chung K; Gardner TS; Cantor CR; Collins JJ
    Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8414-9. PubMed ID: 15159530
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Probiotic Properties of Escherichia coli Nissle in Human Intestinal Organoids.
    Pradhan S; Weiss AA
    mBio; 2020 Jul; 11(4):. PubMed ID: 32636253
    [No Abstract]   [Full Text] [Related]  

  • 51. Probiotic
    Park K; Park S; Nagappan A; Ray N; Kim J; Yoon S; Moon Y
    Nutrients; 2021 Mar; 13(3):. PubMed ID: 33804493
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent advances in high-throughput metabolic engineering: Generation of oligonucleotide-mediated genetic libraries.
    Li Y; Mensah EO; Fordjour E; Bai J; Yang Y; Bai Z
    Biotechnol Adv; 2022 Oct; 59():107970. PubMed ID: 35550915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.
    Khan DD; Lagerbäck P; Malmberg C; Kristoffersson AN; Wistrand-Yuen E; Sha C; Cars O; Andersson DI; Hughes D; Nielsen EI; Friberg LE
    Int J Antimicrob Agents; 2018 Mar; 51(3):399-406. PubMed ID: 29127049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Engineered E. coli that detect and respond to gut inflammation through nitric oxide sensing.
    Archer EJ; Robinson AB; Süel GM
    ACS Synth Biol; 2012 Oct; 1(10):451-7. PubMed ID: 23656184
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rock-paper-scissors: Engineered population dynamics increase genetic stability.
    Liao MJ; Din MO; Tsimring L; Hasty J
    Science; 2019 Sep; 365(6457):1045-1049. PubMed ID: 31488693
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Using the CRISPR-Cas System to Positively Select Mutants in Genes Essential for Its Function.
    Yosef I; Goren MG; Edgar R; Qimron U
    Methods Mol Biol; 2015; 1311():233-50. PubMed ID: 25981477
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Type III-A CRISPR immunity promotes mutagenesis of staphylococci.
    Mo CY; Mathai J; Rostøl JT; Varble A; Banh DV; Marraffini LA
    Nature; 2021 Apr; 592(7855):611-615. PubMed ID: 33828299
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic microbes for infectious disease.
    Wong CK; Tan MH; Rasouliha BH; Hwang IY; Ling H; Poh CL; Chang MW
    Methods Mol Biol; 2014; 1151():117-33. PubMed ID: 24838883
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Escherichia coli vectors having stringently repressible replication origins allow a streamlining of Crispr/Cas9 gene editing.
    Srinivas S; Hu Z; Cronan JE
    Plasmid; 2019 May; 103():53-62. PubMed ID: 31047915
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CRISPR-Enabled Tools for Engineering Microbial Genomes and Phenotypes.
    Tarasava K; Oh EJ; Eckert CA; Gill RT
    Biotechnol J; 2018 Sep; 13(9):e1700586. PubMed ID: 29917318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.